Ten years ago, the first melanoma patient was successfully treated by vaccination with a short peptide — this 'MAGE' was, in fact, the first tumour-specific T-cell epitope ever defined. Since then, a number of clinical vaccination studies have underlined the potential of tumour-specific T-cell epitopes. Stefan Stevanovic considers how we might identify more epitopes to improve their efficacy as an anticancer treatment. reviews Identification of tumour-associated T-cell epitopes for vaccine development STEFAN STEVANOVIC Nature Reviews Cancer 2, 514 (July 2002) Full Text:http://www.nature.com/cgi-taf/DynaPage.taf?file=/nrc/journal/v2/n7/full/nrc841_fs.html